Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome

Summary

This will be a single-site, open-label study in patients with primary Sjogren's syndrome. The aim of this clinical trial is to evaluate the safety and efficacy of anti-BTLA agonist therapy (LY3361237) in treating patients with primary Sjogren's syndrome. The primary objective is to evaluate the efficacy of LY3361237 in patients with primary Sjogren's syndrome by assessing changes in the Sjogren's Tool for Assessing Response (STAR) after 12 weeks of treatment. The secondary objective is to determine the effect of LY3361237 on glandular changes measured by PET/MRI.

Timeline

Start

2025-01-01

Primary completion

2027-01-01

Completion

2028-01-01

Outcome

Outcome not reported

Stopped: “Drug unavailable”

Drugs

Indications